Authors
Latest:
New Product Planning: The Function's Evolution in PharmaWith an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Latest:
The C-Suite’s Frontline Workers in Digital ChangeHow the CIO role has transformed and strengthened against the backdrop of COVID-19.
Latest:
The Agile Future of Medical Information: Meeting 21st-Century Demands for HealthcareCOVID-19 pandemic has accelerated raised expectations for medical information professionals.
Latest:
At the Heart of Pharma: ESG has Arrived as a Central StrategyPharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.
Latest:
Is Your Demand Side Platform (DSP) Ready for the Cookieless Future?A cookieless future is on the horizon, so marketers across all industries are being forced to rethink their strategies and plan for the future. What does that entail?
Latest:
Realizing the NHS’s Digital PotentialWesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.
Latest:
Scientific Discussion Online: How KOLs and Medical Affairs are Moving Scientific Discussion into the Digital SpaceNow Available On Demand! Over the last five years there has been an acceleration of Key Opinion Leaders discussing science in the digital space on social media, forums, news, and the web. Join Dr. Ikenna Ogbaa, Executive Medical Director Cardiovascular and Renal at Bayer Pharmaceuticals and Scott Thompson, Co-CEO at Acceleration Point, as they discuss how medical affairs teams are using digital platforms to successfully engage with KOLs.
Latest:
Four Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Latest:
Cleared and Graded: Modernizing the 510(k) PathwayDue to increasing complexity of modern technology, FDA should consider updating its 510(k) process.
Latest:
Navigating PV Divergence: Compliance Tips for New EntrantsWith small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.
Latest:
COVID-19: Is the Vaccine Race Over?Cliodhna McDonough and Emily Lockey give a UK perspective on the potential pros and cons of the three leading candidates in the COVID-19 vaccine race.
Latest:
The Antibody-Drug Conjugate RenaissanceHow next-generation ADCs are raising the bar in cancer treatment.
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Commercial Models for the Changing Life Sciences MarketLife sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Latest:
Commercializing Cannabis and Patent LitigationHow the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.
Latest:
Patient Treatment & Travel: The Need for Stepped-Up SupportDesigning an effective travel and lodging patient hub program in pharma.
Latest:
The Death Knell of Pharma HCP WebsitesShould pharma brands still maintain dedicated websites to engage HCPs? Are they effective and trustworthy sources of information that offer intuitive and helpful experiences for the user?
Latest:
Where Caremark Meets Park: A New Era of Regulatory Compliance and Criminal LiabilityThe Caremark and Park doctrines require directors and managers of life sciences companies to address regulatory compliance proactively and vigorously.
Latest:
Twenty Years of GrowthLearn how Frontage Laboratories started, recent growth and expansion, and the future vision of Frontage
Latest:
Fast-Track Your Real World Data SearchNow Available On Demand! Join this webinar to learn a new way to quickly identify the right real world data sources. IQVIA Health Data Catalog makes assessing RWD fast and easy with 2000+ unique global data assets, 200+ variables describing patient data, and up-to-date profiles to efficiently compare which is most relevant for your project.
Latest:
Are We Entering the Nuclear Medicine Industrial Revolution?Achieving better outcomes for patients and advancing the fields of nuclear medicine and oncology are not just about adopting new technologies, but also about embracing a profound change in how care is delivered.
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
Three Ways Life Sciences Can Educate Stakeholders About BiosimilarsThere are several strategies life sciences companies can use to benefit from biosimilars.
Latest:
How to Build and Maintain Relationships with High-Profile ClientsFor pharma manufacturers, the primary requirement for working with high-profile clients is matching their organizational level of urgency and organization.
Latest:
Unlocking the Potential of AI in Healthcare–5 Key TakeawaysThe technology has the potential to be implemented across multiple aspects of the industry.
